Cognition Therapeutics Extends Expanded Access Program for Zervimesine in Dementia with Lewy Bodies, Enhancing Patient Experience and Long-Term Safety Data.

Cognition Therapeutics has extended the duration of its expanded access program for zervimesine (CT1812) in dementia with Lewy bodies (DLB), allowing several more months of treatment. The program has enrolled 32 individuals at eight sites, with favorable feedback from participants and their care partners. The EAP is part of Cognition's larger clinical development program in DLB, which includes the Phase 2 SHIMMER study and planned clinical programs. The company conducted a Type C meeting with the FDA on January 21, 2026, to review findings from the SHIMMER study. Meeting minutes are expected in February.